GlassScriptPhysician profile
Jarret Helstern
NPI 1992169015
$109,880.98
in general payments reported to CMS, 2019-2025
40 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,428 · 2022: $9,729 · 2023: $34K · 2024: $52K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $15K · Travel and Lodging: $10K · Consulting Fee: $1,353 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,918.75 |
| Food and Beverage | $15,166.83 |
| Travel and Lodging | $10,092.18 |
| Consulting Fee | $1,352.50 |
| Education | $193.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $53,110.21 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $42,720.30 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,376.93 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,739.98 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $1,379.17 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $1,177.38 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $993.23 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $665.91 | 2023-2025 | Sunosi, Auvelity |
| Corium, LLC | $548.93 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $490.87 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $473.00 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $458.19 | 2021-2025 | Trintellix |
| Neos Therapeutics, LP | $357.91 | 2023-2025 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $313.00 | 2021-2022 | |
| Pfizer INC. | $264.42 | 2023-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $246.15 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $244.07 | 2021-2025 | Wellbutrin, Aplenzin |
| Idorsia Pharmaceuticals US INC | $189.19 | 2022-2023 | Quviviq |
| Tris Pharma INC | $170.03 | 2023-2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $154.15 | 2023-2025 | Rexulti |
| Harmony Biosciences LLC | $153.21 | 2021-2025 | |
| Sage Therapeutics, LLC | $145.52 | 2023 | |
| Ironshore Pharmaceuticals INC. | $142.12 | 2022-2024 | Jornay Pm |
| Lilly USA, LLC | $138.41 | 2024-2025 | Zepbound |
| Biogen, INC. | $138.25 | 2021-2025 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $135.56 | 2025 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $134.88 | 2021-2023 | |
| Indivior INC. | $126.00 | 2022-2024 | Perseris |
| Eisai INC. | $123.97 | 2021 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Noven Therapeutics, LLC | $90.30 | 2023-2025 | Xelstrym |
| Almatica Pharma LLC | $69.13 | 2022-2023 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $67.58 | 2025 | Jornay Pm |
| Braeburn INC. | $47.41 | 2024-2025 | Brixadi |
| Uswm, LLC | $43.62 | 2023 | Zimhi, Lucemyra |
| Acadia Pharmaceuticals INC | $39.30 | 2021-2023 | Nuplazid |
| Allergan, INC. | $26.34 | 2021 | |
| Livanova USA, INC. | $25.31 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Tempus Ai, INC | $23.37 | 2024 | |
| Novo Nordisk INC | $22.68 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarret Helstern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.